Xos (XOS) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
13 May, 2026Voting matters and shareholder proposals
Six proposals up for vote include election of three Class II directors, auditor ratification, equity incentive plan amendment, advisory votes on executive compensation and its frequency, and approval of a major convertible note transaction (Proposal 6).
Board recommends voting FOR all director nominees and proposals, and for a ONE YEAR frequency on the say-on-pay vote.
Proxy cards remain valid; shareholders can vote online, by phone, by mail, or at the virtual meeting.
Related party transactions
Third Amended and Restated Convertible Promissory Note with Aljomaih reduces conversion price to $12.00 per share and adds a mandatory conversion feature if stock trades above $16.00 for 20 out of 30 days.
As of May 11, 2026, Aljomaih may beneficially own 3,738,303 shares, or about 28% of outstanding common stock, including shares acquirable upon note conversion.
Proposal 6 seeks approval for potential issuance of 20% or more of outstanding shares at below Nasdaq Minimum Price, possibly triggering a change of control.
Shareholder rights and capital structure
Approval of Proposal 6 would authorize issuance of a significant number of shares to Aljomaih, potentially altering control and capital structure.
Outstanding principal of $15.5 million on the note is convertible into 1,291,666 shares of common stock.
Latest events from Xos
- Record Q1 revenue and gross margin, but ongoing losses and liquidity risks remain.XOS
Q1 202614 May 2026 - Shareholders will vote on director elections, equity plan expansion, and a major convertible note share issuance.XOS
Proxy filing4 May 2026 - Key votes include director elections, auditor ratification, and approval of major stock issuance.XOS
Proxy filing4 May 2026 - 2025 saw positive free cash flow, margin gains, narrowed losses, and strong growth in powertrain and hub segments.XOS
Q4 202528 Apr 2026 - Shareholders will vote on key governance, compensation, and capital structure proposals at the 2026 meeting.XOS
Proxy filing24 Apr 2026 - Q2 2024 revenue up 227% year-over-year, 90 units delivered, but going concern risk remains.XOS
Q2 20241 Feb 2026 - Q3 revenue reached $15.8M with 18.1% gross margin, but liquidity and market risks remain.XOS
Q3 202414 Jan 2026 - Record revenue, positive gross margin, and free cash flow highlight a strong 2024 and outlook.XOS
Q4 202426 Dec 2025 - Shareholders will vote on director elections, auditor ratification, and an expanded equity plan.XOS
Proxy Filing1 Dec 2025